Knowledge Center

Topic
Close
Clear
13.04.2021

When and why should my API be a new crystalline polymorph, amorphous, a co-crystal, or an alternative salt?

When and why should my API be a new crystalline polymorph, amorphous, a co-crystal, or an alternative salt?
Maytal Piran
17.08.2020

Teva api Adopts New Nitrosamine Regulations

Teva api Adopts New Nitrosamine Regulations
Olga Pogrebinsky
10.08.2020

Navigating China’s API Regulations

Navigating China’s API Regulations
Olga Pogrebinsky
24.06.2020

Creatively using co-crystals to produce alternative generic products

Creatively using co-crystals to produce alternative generic products
Maytal Piran
31.10.2019

Teva api Offers New API Sterilization Services

Teva api Offers New API Sterilization Services
07.04.2019

A global API supplier that understands the API industry!

A global API supplier that understands the API industry!
29.01.2019

Trends in the API industry that you should be aware of (2019)

Trends in the API industry that you should be aware of (2019)
Jordan Rudner
04.11.2018

Why changes in the API manufacturing landscape is great news for Teva api

Why changes in the API manufacturing landscape is great news for Teva api

Active pharmaceutical Ingredient production is a high tech, high stakes business

Active pharmaceutical Ingredient production is a high tech, high stakes business
View more articles

Last site inspections

  • Nov 16, 2021 Teva API had a successful inspection in the Teva api India Gajraula site by UP State FDA
  • Jul 20, 2021 Teva API had a successful inspection in the Teva api Czech site by SUKL
  • Jun 22-23, 2021 Teva API had a successful inspection in the Teva api India Malanpur site by Local MOH
View all Site Inspections

Last regulatory updates

  • Dec 29, 2021 EU DMF
  • Dec 14, 2021 US DMF
  • Nov 01, 2021 New CA DMF for is available.
View all Regulatory Updates